论文部分内容阅读
目的:观察格列齐特缓释片对初诊2型糖尿病患者胰岛素抵抗和胰岛β细胞功能的影响。方法:30例2型糖尿病患者口服格列齐特缓释片30mg·qd。按HOMA模型计算胰岛素抵抗指数(HOMA -IR)和胰岛素分泌指数(HOMA-IS)。结果:格列齐特级释片治疗1 2周后,FPG、PG2h、HbA1 c、HOMA -IR均明显下降,HOMA -IS明显增加(P <0 .0 1或P <0 .0 5 )。多元回归分析显示餐前及餐后血糖值变化与HOMA -IR的变化相关。结论:格列齐特缓释片治疗初诊的2型糖尿病,可明显改善胰岛素抵抗和β细胞分泌功能,其中前者可能得益于血糖的明显降低。
Objective: To observe the effects of gliclazide on insulin resistance and pancreatic β-cell function in newly diagnosed type 2 diabetic patients. Methods: Thirty patients with type 2 diabetes were treated with gliclazide 30 mg · qd. The HOMA-IR and HOMA-IS were calculated according to HOMA model. Results: After treated with gliclazide for 1 week, FPG, PG2h, HbA1c and HOMA-IR decreased significantly and HOMA-IS increased significantly (P <0.01 or P <0.05). Multivariate regression analysis showed that changes in pre and postprandial blood glucose levels were associated with changes in HOMA-IR. Conclusion: Gliclazide sustained-release tablets in the treatment of newly diagnosed type 2 diabetes mellitus can significantly improve insulin resistance and β-cell secretory function, of which the former may benefit from significantly lower blood glucose.